Peter Charles Schmidt, MD
Pain Management · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Schmidt’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A121820 · Current
Licensed to practise in California · since 2012 · expires 2027-11-30 · University of Colorado School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$6,642
Medicare paid this office $6,642 for 47 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (45+ min) | 12 | $1,631 | $136 |
Who their Medicare patients are
47 Original Medicare patients in 2024. Average age 72 · Women 47% · Also on Medicaid 28% · Health risk score 3.10. Sicker patients than 9 in 10 peers; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 70% · Cancer 57% · Diabetes 43% · Chronic kidney disease 36% · Depression 36% · Atrial fibrillation 23%.
The office billed $30,514, Medicare allowed $8,719 and paid $6,642; for 66 services of 11 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 47 | 66 | 72 | 3.10 | $30,514 | $6,642 |
| 2023 | 55 | 72 | 69 | 3.37 | $39,593 | $7,688 |
| 2022 | 29 | 37 | 70 | 3.14 | $21,931 | $3,722 |
| 2021 | 65 | 93 | 71 | 3.01 | $56,270 | $10,113 |
| 2020 | 90 | 160 | 69 | 2.57 | $79,112 | $13,736 |
| 2019 | 111 | 257 | 68 | 2.71 | $53,215 | $19,494 |
| 2018 | 78 | 153 | 70 | 2.60 | $29,416 | $10,908 |
| 2017 | 66 | 106 | 71 | 2.51 | $28,589 | $10,250 |
| 2016 | 30 | 51 | 71 | 1.43 | $14,616 | $2,685 |
| 2015 | 15 | 29 | 62 | 1.92 | $7,642 | $1,055 |
| 2013 | 13 | 14 | 76 | 1.29 | $16,926 | $2,589 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| New patient visit (60+ min) | 17 | $2,839 | $167 |
| Return visit (30+ min) | 13 | $1,355 | $85 |
2021: 3 services
| New patient visit (60+ min) | 23 | $3,853 | $168 |
| New patient visit (45+ min) | 17 | $2,153 | $127 |
| Long return visit (40+ min) | 12 | $1,828 | $141 |
2020: 3 services
| New patient visit (60+ min) | 44 | $6,746 | $153 |
| Long return visit (40+ min) | 29 | $2,960 | $95 |
| Ultrasonic guidance for needle placement | 17 | $765 | $27 |
2019: 4 services
| New patient visit (60+ min) | 57 | $8,367 | $147 |
| Long return visit (40+ min) | 41 | $6,270 | $96 |
| Ultrasonic guidance for needle placement | 37 | $1,816 | $29 |
| Injection of trigger points, 3 or more muscles | 21 | $1,523 | $38 |
2018: 4 services
| Long return visit (40+ min) | 35 | $4,350 | $85 |
| New patient visit (60+ min) | 25 | $3,763 | $151 |
| Ultrasonic guidance for needle placement | 20 | $946 | $29 |
| Injection of trigger points, 3 or more muscles | 13 | $908 | $39 |
2017: 4 services
| Long return visit (40+ min) | 29 | $4,683 | $96 |
| New patient visit (60+ min) | 21 | $3,070 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,231 | $65 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,077 | $90 |
2016: 1 service
| Ultrasonic guidance for needle placement | 15 | $390 | $26 |
Drugs they prescribed that Part D paid
$7,681
Pharmacies billed $7,681 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 25% of their Part D prescriptions (94 of 374) in 2024. At or below the middle of the specialty; the typical pain management clinician is at 44%. Long-acting opioids: 30% of their opioid prescriptions.
371 generic and fewer than 11 brand-name prescriptions · $7,681 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 74 | $1,488 | $20 |
| Celecoxib | 30 | $918 | $31 |
| Buprenorphine | 14 | $645 | $46 |
| Oxycodone | 17 | $613 | $36 |
| Pregabalin | 37 | $575 | $16 |
See all 9 drugs
| Gabapentin | 74 | $1,488 | $20 |
| Celecoxib | 30 | $918 | $31 |
| Buprenorphine | 14 | $645 | $46 |
| Oxycodone | 17 | $613 | $36 |
| Pregabalin | 37 | $575 | $16 |
| Methadone | 20 | $330 | $16 |
| Hydrocodone-Acetaminophen | 19 | $324 | $17 |
| Morphine Sulfate | 14 | $317 | $23 |
| Meloxicam | 12 | $17 | $1 |
Year by year
| 2024 | 374 | 51 | 25% (94) | None | $7,681 |
| 2023 | 406 | 53 | 29% (119) | 3% | $18,631 |
| 2022 | 363 | 52 | 39% (141) | 3% | $15,593 |
| 2021 | 516 | 65 | 39% (200) | 5% | $27,195 |
| 2020 | 472 | 74 | 34% (161) | 5% | $23,903 |
| 2019 | 475 | 70 | 36% (171) | 10% | $33,037 |
| 2018 | 211 | 43 | 39% (82) | 13% | $18,531 |
| 2017 | 194 | 30 | 31% (60) | 15% | $15,787 |
| 2016 | 19 | None | None | None | $1,799 |
| 2014 | 24 | None | None | 50% | $3,305 |
| 2013 | 14 | None | None | None | $2,988 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Celecoxib | 57 | $1,746 | $31 |
| Gabapentin | 47 | $1,133 | $24 |
| Pregabalin | 38 | $1,087 | $29 |
| Hydrocodone-Acetaminophen | 27 | $824 | $31 |
| Morphine Sulfate | 13 | $412 | $32 |
| Methadone | 26 | $374 | $14 |
| Desipramine | 12 | $352 | $29 |
| Oxycodone-Acetaminophen | 15 | $343 | $23 |
| Nortriptyline | 12 | $308 | $26 |
| Lorazepam | 14 | $116 | $8 |
2022: 12 drugs
| Celecoxib | 40 | $2,122 | $53 |
| Pregabalin | 22 | $2,007 | $91 |
| Fentanyl | 19 | $1,888 | $99 |
| Gabapentin | 54 | $1,467 | $27 |
| Methadone | 40 | $794 | $20 |
| Morphine Sulfate | 15 | $737 | $49 |
| Hydrocodone-Acetaminophen | 31 | $724 | $23 |
| Buprenorphine | 11 | $663 | $60 |
| Oxycodone | 11 | $528 | $48 |
| Oxycodone-Acetaminophen | 19 | $264 | $14 |
| Nortriptyline | 16 | $173 | $11 |
| Bupropion Xl | 12 | $162 | $13 |
2021: 12 drugs
| Pregabalin | 52 | $3,279 | $63 |
| Celecoxib | 36 | $2,795 | $78 |
| Buprenorphine | 27 | $2,405 | $89 |
| Fentanyl | 21 | $1,961 | $93 |
| Gabapentin | 52 | $1,563 | $30 |
| Morphine Sulfate | 11 | $1,333 | $121 |
| Methadone | 65 | $1,314 | $20 |
| Oxycodone | 27 | $666 | $25 |
| Oxycodone-Acetaminophen | 28 | $529 | $19 |
| Hydrocodone-Acetaminophen | 25 | $519 | $21 |
| Zolpidem | 16 | $271 | $17 |
| Nortriptyline | 13 | $185 | $14 |
2020: 13 drugs
| Celecoxib | 52 | $3,292 | $63 |
| Fentanyl | 24 | $2,805 | $117 |
| Buprenorphine | 15 | $1,594 | $106 |
| Oxycodone | 31 | $1,510 | $49 |
| Gabapentin | 57 | $1,428 | $25 |
| Pregabalin | 24 | $1,144 | $48 |
| Methadone | 30 | $759 | $25 |
| Oxycodone-Acetaminophen | 29 | $729 | $25 |
| Hydrocodone-Acetaminophen | 31 | $605 | $20 |
| Nortriptyline | 13 | $51 | $4 |
| Zolpidem | 12 | $37 | $3 |
| Sertraline | 11 | $34 | $3 |
| Alprazolam | 13 | $19 | $1 |
2019: 11 drugs
| Lyrica | 12 | $8,460 | $705 |
| Celecoxib | 62 | $4,318 | $70 |
| Gabapentin | 76 | $3,049 | $40 |
| Fentanyl | 26 | $1,996 | $77 |
| Desipramine | 22 | $1,554 | $71 |
| Oxycodone | 34 | $1,410 | $41 |
| Duloxetine | 15 | $1,189 | $79 |
| Hydrocodone-Acetaminophen | 27 | $840 | $31 |
| Oxycodone-Acetaminophen | 20 | $775 | $39 |
| Methadone | 36 | $603 | $17 |
| Zolpidem | 12 | $23 | $2 |
2018: 6 drugs
| Gabapentin | 43 | $1,952 | $45 |
| Desipramine | 18 | $1,654 | $92 |
| Hydrocodone-Acetaminophen | 15 | $355 | $24 |
| Oxycodone-Acetaminophen | 14 | $257 | $18 |
| Methadone | 17 | $194 | $11 |
| Omeprazole | 11 | $65 | $6 |
2017: 6 drugs
| Lyrica | 13 | $6,561 | $505 |
| Celecoxib | 17 | $1,763 | $104 |
| Gabapentin | 39 | $1,595 | $41 |
| Oxycodone | 14 | $795 | $57 |
| Hydrocodone-Acetaminophen | 11 | $138 | $13 |
| Omeprazole | 15 | $79 | $5 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1891968608
- Licence
- CA A121820California A121820: Current · expires 2027-11-30
- Trained
- University of Colorado School of Medicine, Denver, 2008
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207LP2900X (207LP2900X); Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-04-12
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.